Turning to freshwater sources to fight drug-resistant tuberculosis, other infections

April 8, 2015, American Chemical Society
Turning to freshwater sources to fight drug-resistant tuberculosis, other infections

The discovery of antibiotics produced by soil fungi and bacteria gave the world life-saving medicine. But new antimicrobials from this resource have become scarce as the threat of drug resistance grows. Now, scientists have started mining lakes and rivers for potential pathogen-fighters, and they've found one from Lake Michigan that is effective against drug-resistant tuberculosis. Their report on the new compound appears in the journal ACS Infectious Diseases.

Brian T. Murphy and colleagues point out that the emergence of drug-resistant strains of Mycobacterium tuberculosis is a serious, global health threat. In 2013, these bacteria caused 210,000 deaths globally and 480,000 infections, of which more than half were in China, India and Russia, according to the World Health Organization. The development of to fight them has not yet yielded an optimal solution.

Despite a few recent successes, scientists are having a hard time finding new candidates from soil-dwelling microbes. Murphy's team wanted to see whether bacteria that live in freshwater—a habitat that has been largely unexplored for this purpose—could be a new source of antibiotics.

The researchers screened an extensive collection of freshwater bacteria metabolites and identified a new compound that stops the growth of M. tuberculosis. In lab tests, the compound worked at least as well as current treatments for tuberculosis, and it inhibited drug-resistant strains.

Explore further: Key to tuberculosis cure could lie underwater

More information: Diaza-anthracene Antibiotics from a Freshwater-Derived Actinomycete with Selective Antibacterial Activity toward Mycobacterium tuberculosis ACS Infect. Dis., Article ASAP. DOI: 10.1021/acsinfecdis.5b00005

Abstract
Multidrug- and extensively drug-resistant strains of Mycobacterium tuberculosis are resistant to first- and second-line drug regimens and resulted in 210,000 fatalities in 2013. In the current study, we screened a library of aquatic bacterial natural product fractions for their ability to inhibit this pathogen. A fraction from a Lake Michigan bacterium exhibited significant inhibitory activity, from which we characterized novel diazaquinomycins H and J. This antibiotic class displayed an in vitro activity profile similar or superior to clinically used anti-tuberculosis agents and maintained this potency against a panel of drug-resistant M. tuberculosis strains. Importantly, these are among the only freshwater-derived actinomycete bacterial metabolites described to date. Further in vitro profiling against a broad panel of bacteria indicated that this antibiotic class selectively targets M. tuberculosis. Additionally, in the case of this pathogen we present evidence counter to previous reports that claim the diazaquinomycins target thymidylate synthase in Gram-positive bacteria. Thus, we establish freshwater environments as potential sources for novel antibiotic leads and present the diazaquinomycins as potent and selective inhibitors of M. tuberculosis.

Related Stories

Key to tuberculosis cure could lie underwater

March 8, 2013
The search for a cure for deadly infectious diseases has led Brian Murphy deep underwater. Murphy, assistant professor of medicinal chemistry and pharmacognosy at the University of Illinois at Chicago, is collecting actinomycete ...

Researchers discover potential treatment for drug-resistant tuberculosis

February 20, 2015
Researchers at the University of Georgia have developed a new small molecule drug that may serve as a treatment against multi-drug resistant tuberculosis, a form of the disease that cannot be cured with conventional therapies. ...

Potential new drug for tuberculosis

August 5, 2013
A new drug capable of inhibiting growth of Mycobacterium tuberculosis is reported this week in Nature Medicine. The findings may improve therapeutic options for the treatment of drug resistant tuberculosis (TB).

Improving detection of drug-resistant tuberculosis

May 2, 2012
(Medical Xpress) -- European researchers are developing new assays to detect drug resistant strains of Mycobacterium tuberculosis.

Scientists reveal how natural antibiotic kills tuberculosis bacterium

September 17, 2012
A natural product secreted by a soil bacterium shows promise as a new drug to treat tuberculosis report scientists in a new study published in EMBO Molecular Medicine. A team of scientists working in Switzerland has shown ...

Recommended for you

A versatile vaccine that can protect mice from emerging tick-borne viruses

December 18, 2018
A group of researchers led by Michael Diamond of Washington University School of Medicine in St. Louis have developed a vaccine that is effective in mice against Powassan virus, an emerging tick-borne virus that can cause ...

How cholera bacteria make people so sick

December 18, 2018
The enormous adaptability of the cholera bacterium explains why it is able to claim so many victims. Professor Ariane Briegel from the Leiden Institute of Biology has now discovered that this adaptability is due to rapid ...

Green leafy vegetables may prevent liver steatosis

December 17, 2018
A larger portion of green leafy vegetables in the diet may reduce the risk of developing liver steatosis, or fatty liver. In a study published in PNAS researchers from Karolinska Institutet in Sweden show how a larger intake ...

Discovery of novel mechanisms that cause migraines

December 17, 2018
Researchers at CNRS, Université Côte d'Azur and Inserm have demonstrated a new mechanism related to the onset of migraine. They found how a mutation that causes dysfunction in a protein which inhibits neuronal electrical ...

RNA processing and antiviral immunity

December 14, 2018
The RIG-I like receptors (RLRs) are intracellular enzyme sentries that detect viral infection and initiate a first line of antiviral defense. The cellular molecules that activate RLRs in vivo are not clear.

Faster test for Ebola shows promising results in field trials

December 13, 2018
A team of researchers with members from the U.S., Senegal and Guinea, in cooperation with Becton, Dickinson and Company (BD), has developed a faster test for the Ebola virus than those currently in use. In their paper published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.